Clinical Trial Update: A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

This is a completed Phase 1 clinical trial update for Janssen investigational agents JNJ-64264681 and JNJ-67856633 in participants with Non-Hodgkin lymphoma and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• JNJ-64264681
• JNJ-67856633

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED